According to our latest research offering “Russian Pharma Sector Forecast to 2013”, highly prolific Russian pharmaceutical industry is expected to grow at a CAGR of around 13% during 2011-2013. The industry will prosper amid the growing concerns of health conditions and the high dependence of the country on imported drugs. Additionally, new reforms being introduced by the Russian Government will not only streamline the industry, it will also help in the upliftment of the domestic manufacturers. Our report evaluates the potential of the pharma industry in post recessionary scenario and has also examined its future growth prospects.
Besides dynamic government support, the industry will witness stupendous growth due to the influx of foreign investments as many global leaders are planning to establish their production units in Russia. Further, various factors, such as growing healthcare spending and enforcement of obligatory and voluntary insurance schemes will improve the purchasing power of the population, resulting in the increase of sales of high-priced drugs. Moreover, rise in the prevalence of infectious diseases, like HIV/AIDS and other lifestyle related chronic diseases would provide a more conducive environment for the growth of the pharmaceutical industry in the country.
The in-depth analysis of the market drivers suggests that the Russian market shows immense growth potential and is at the initial stages of development. Additionally, increasing investments from private players will boost the commercial drugs segment to occupy the largest market share by 2013. Besides the drivers, our report identifies the major roadblocks being faced by the pharma industry during the forecast period (2011-2013).
Additionally, our report “ Russian Pharma Sector Forecast to 2013”, provides extensive research and rational analysis, which has been based on reliable statistics of the Russian pharma sector. Impact of the recent economic downturn has been considered in the forecasting as well. Moreover, the report covers aspects, such as leading drugs, segment-wise break up, and information on major therapy areas to provide a strategic insight into the market. The report provides a comprehensive outlook of the industrial developments and competitive landscapes to enable clients understand the market structure and its progress in coming years.
For more information visit: http://www.rncos.com/Report/IM243.htm |
